News about diabetes • obesity

New @Nature A quintuple [GLP-1 + 4 other] receptor agonist drug that exceeds effects of the dual receptor (GLP-1 and GIP, tirzepatide) in the experimental model vs diabetes and obesity (in case you thought a dual receptor was max effect, as also seen with retatrutide, a triple pic.x.com/bvjCbj5Y6P

With the launch of @EliLillyandCo 's orforglipron (Foundayo) for #obesity, many clinicians are asking how to switch patients who are already on a #GLP1 like semaglutide: Evidence-informed TLDR: 👉 semaglutide 1.5-2.0 mg/wk ≅ orforglipron max dose for #weightloss 👉 If switching pic.x.com/W74vUgdiZK

A hybrid drug used GLP-1/GIP signaling as a “door opener” to smuggle a second metabolic modulator into target cells; in mice, it outperformed reference treatments at far lower doses. @nature doi.org/hbztb7 medicalxpress.com/news/2026-04-molecule-effects-drug-concept-obesity.html?utm_source=twitter.com&utm_medium=social&utm_campaign=v2

Hi guys, our new paper is out! The GLP1–GIP–PPARα/γ/δ quintuple agonist, a novel strategy synergizing polypharmacology with specificity. Below is a hopeful explainer to avoid confusion. Give it a share. Not paid by twitter doing it for the love of the game www.nature.com/articles/s41586-026-10427-5